Montis Financial LLC Sells 61 Shares of Stryker Co. (NYSE:SYK)

Montis Financial LLC lowered its position in Stryker Co. (NYSE:SYK) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,265 shares of the medical technology company’s stock after selling 61 shares during the period. Montis Financial LLC’s holdings in Stryker were worth $816,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Picton Mahoney Asset Management increased its position in shares of Stryker by 12.1% in the 4th quarter. Picton Mahoney Asset Management now owns 762 shares of the medical technology company’s stock valued at $275,000 after buying an additional 82 shares in the last quarter. Associated Banc Corp increased its position in shares of Stryker by 1.4% in the 4th quarter. Associated Banc Corp now owns 20,894 shares of the medical technology company’s stock valued at $7,523,000 after buying an additional 290 shares in the last quarter. HMV Wealth Advisors LLC bought a new position in Stryker during the 4th quarter worth about $841,000. Ironwood Investment Counsel LLC increased its holdings in Stryker by 0.9% during the 4th quarter. Ironwood Investment Counsel LLC now owns 3,323 shares of the medical technology company’s stock worth $1,196,000 after purchasing an additional 30 shares in the last quarter. Finally, First National Trust Co increased its holdings in Stryker by 4.7% during the 4th quarter. First National Trust Co now owns 18,187 shares of the medical technology company’s stock worth $6,548,000 after purchasing an additional 820 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have issued reports on SYK shares. Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $370.00 to $445.00 in a report on Monday, December 2nd. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Finally, Wells Fargo & Company increased their price objective on shares of Stryker from $427.00 to $435.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Stryker currently has an average rating of “Moderate Buy” and an average price target of $421.90.

Stryker Trading Up 1.7 %

Shares of NYSE:SYK opened at $369.96 on Friday. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a market capitalization of $141.17 billion, a P/E ratio of 47.68, a price-to-earnings-growth ratio of 2.93 and a beta of 0.95. The company has a 50-day simple moving average of $383.04 and a 200 day simple moving average of $373.37. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company posted $3.46 earnings per share. Sell-side analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.91%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.